

Alzheimer's disease: The amyloid cascade hypothesis: A

Journal of Alzheimer's Disease

9, 151-153

DOI: 10.3233/jad-2006-9s317

Citation Report

#	ARTICLE	IF	CITATIONS
1	Amyloid- $\beta$ in Alzheimer Disease: The Null versus the Alternate Hypotheses. <i>Journal of Pharmacology and Experimental Therapeutics</i> , 2007, 321, 823-829.	1.3	144
2	Clinicopathologic Correlations in a Large Alzheimer Disease Center Autopsy Cohort. <i>Journal of Neuropathology and Experimental Neurology</i> , 2007, 66, 1136-1146.	0.9	258
3	A copper-binding site in the cytoplasmic domain of BACE1 identifies a possible link to metal homeostasis and oxidative stress in Alzheimer's disease. <i>Biochemical Society Transactions</i> , 2007, 35, 571-573.	1.6	25
4	Quick Assembly of 1,4-Diphenyltriazoles as Probes Targeting $\beta$ -Amyloid Aggregates in Alzheimer's Disease. <i>Journal of Medicinal Chemistry</i> , 2007, 50, 3380-3387.	2.9	55
6	Role of HMG-CoA Reductase Inhibitors in Neurological Disorders. <i>Drugs</i> , 2007, 67, 2111-2120.	4.9	34
8	Synthesis and evaluation of indolyl- and indolylphenylacetylenes as PET imaging agents for $\beta$ -amyloid plaques. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2008, 18, 4823-4827.	1.0	15
9	Synthesis of fluorescent probes based on stilbenes and diphenylacetylenes targeting $\beta$ -amyloid plaques. <i>Tetrahedron Letters</i> , 2008, 49, 3395-3399.	0.7	31
10	Failure of elimination of amyloid- $\beta$ from the brain in Alzheimer's disease. <i>Progress in Neurology and Psychiatry</i> , 2008, 12, 6-10.	0.4	0
11	MicroRNAs (miRNAs) in Neurodegenerative Diseases. <i>Brain Pathology</i> , 2008, 18, 130-138.	2.1	319
12	Oxidative stress increases levels of endogenous amyloid- $\beta$ peptides secreted from primary chick brain neurons. <i>Aging Cell</i> , 2008, 7, 771-775.	3.0	42
13	The molecular pathology of Alzheimer's disease. <i>Psychiatry (Abingdon, England)</i> , 2008, 7, 1-5.	0.2	21
14	Development, Optimization and Use of Preclinical Behavioral Models to Maximize the Productivity of Drug Discovery for Alzheimer's Disease. , 2008, , 93-157.		10
15	The $\alpha$ -synuclein burden hypothesis of Parkinson disease and its relationship to Alzheimer disease. <i>Experimental Neurology</i> , 2008, 212, 235-238.	2.0	37
16	Emerging amyloid beta (Ab) peptide modulators for the treatment of Alzheimer's disease (AD). <i>Expert Opinion on Emerging Drugs</i> , 2008, 13, 255-271.	1.0	26
17	An Expedient Synthesis of the Fibril Binding Compound FSB via Sequential Pd-Catalyzed Coupling Reactions. <i>Journal of Organic Chemistry</i> , 2008, 73, 3570-3573.	1.7	11
18	Pre-amyloid Lesions and Cerebrovascular Deposits in the Mechanism of Dementia: Lessons from Non- $\beta$ -Amyloid Cerebral Amyloidosis. <i>Neurodegenerative Diseases</i> , 2008, 5, 173-175.	0.8	11
19	Therapeutic Approaches for the Treatment of Alzheimer's Disease: An Overview. , 2007, , 1-24.		5
20	Activation of the Amyloid Cascade in Apolipoprotein E4 Transgenic Mice Induces Lysosomal Activation and Neurodegeneration Resulting in Marked Cognitive Deficits. <i>Journal of Neuroscience</i> , 2008, 28, 4690-4701.	1.7	92

#	ARTICLE	IF	CITATIONS
21	From Aging to Alzheimer's Disease: Unveiling "The Switch" with the Senescence-Accelerated Mouse Model (SAMP8). <i>Journal of Alzheimer's Disease</i> , 2008, 15, 615-624.	1.2	177
22	Down's syndrome and Alzheimer's disease: two sides of the same coin. <i>Future Neurology</i> , 2008, 3, 29-37.	0.9	15
24	Novel Pharmacotherapies for Alzheimer's Disease. <i>Journal of the Korean Medical Association</i> , 2009, 52, 1059.	0.1	10
25	Testosterone regulates Alzheimer's disease pathogenesis. , 2009, , 242-250.		1
26	Diet Quality Is Associated with Better Cognitive Test Performance among Aging Men and Women. <i>Journal of Nutrition</i> , 2009, 139, 1944-1949.	1.3	93
27	Brains With Medial Temporal Lobe Neurofibrillary Tangles But No Neuritic Amyloid Plaques Are a Diagnostic Dilemma But May Have Pathogenetic Aspects Distinct From Alzheimer Disease. <i>Journal of Neuropathology and Experimental Neurology</i> , 2009, 68, 774-784.	0.9	92
28	Animal Models for Alzheimer's Disease and Frontotemporal Dementia: A Perspective. <i>ASN Neuro</i> , 2009, 1, AN20090042.	1.5	31
29	A Common Biological Mechanism in Cancer and Alzheimers Disease?. <i>Current Alzheimer Research</i> , 2009, 6, 196-204.	0.7	165
30	Visualization of Brain Amyloid and Microglial Activation in Mouse Models of Alzheimers Disease. <i>Current Alzheimer Research</i> , 2009, 6, 137-143.	0.7	33
31	FAD-mutation of APP is associated with a loss of its synaptotrophic activity. <i>Neurobiology of Disease</i> , 2009, 35, 258-263.	2.1	10
32	Amyloid- $\beta$ -induced occludin down-regulation and increased permeability in human brain endothelial cells is mediated by MAPK activation. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 14, 1101-12.	1.6	93
33	The rat as an animal model of Alzheimer's disease. <i>Journal of Cellular and Molecular Medicine</i> , 2009, 13, 1034-1042.	1.6	55
34	Mouse models of oxidative phosphorylation defects: Powerful tools to study the pathobiology of mitochondrial diseases. <i>Biochimica Et Biophysica Acta - Molecular Cell Research</i> , 2009, 1793, 171-180.	1.9	33
35	Alzheimer's disease: a light at the end of the tunnel?. <i>Drug Development Research</i> , 2009, 70, 57-59.	1.4	1
36	Tetrahydroxy stilbene glucoside reduces the cognitive impairment and overexpression of amyloid precursor protein induced by aluminum exposure. <i>Neuroscience Bulletin</i> , 2009, 25, 391-396.	1.5	30
37	P-Glycoprotein and Breast Cancer Resistance Protein Restrict Apical-to-Basolateral Permeability of Human Brain Endothelium to Amyloid- $\beta$ . <i>Journal of Cerebral Blood Flow and Metabolism</i> , 2009, 29, 1079-1083.	2.4	108
38	The up-regulation of BACE1 mediated by hypoxia and ischemic injury: role of oxidative stress and HIF1 $\alpha$ . <i>Journal of Neurochemistry</i> , 2009, 108, 1045-1056.	2.1	217
40	Chapter 1 Recent Advances in the Discovery of GSK-3 Inhibitors and a Perspective on their Utility for the Treatment of Alzheimer's Disease. <i>Annual Reports in Medicinal Chemistry</i> , 2009, , 3-26.	0.5	7

#	ARTICLE	IF	CITATIONS
41	A Versatile Approach to $\beta$ -Amyloid Fibril-Binding Compounds Exploiting the Shirakawa/Hayashi Protocol for <i>trans</i> -Alkene Synthesis. <i>Organic Letters</i> , 2009, 11, 999-1002.	2.4	17
42	Protective effect of a triazine-derivative (AA3E2) on $\beta$ -amyloid-induced damages in SK-N-MC cells. <i>Toxicology in Vitro</i> , 2009, 23, 1277-1283.	1.1	8
43	Conformation and topology of amyloid $\beta$ -protein adsorbed on a tethered artificial membrane probed by surface plasmon field-enhanced fluorescence spectroscopy. <i>Journal of Structural Biology</i> , 2009, 168, 117-124.	1.3	8
44	Cell cycle re-entry mediated neurodegeneration and its treatment role in the pathogenesis of Alzheimer's disease. <i>Neurochemistry International</i> , 2009, 54, 84-88.	1.9	125
45	Nanoparticle-chelator conjugates as inhibitors of amyloid- $\beta$ aggregation and neurotoxicity: A novel therapeutic approach for Alzheimer disease. <i>Neuroscience Letters</i> , 2009, 455, 187-190.	1.0	138
46	Development of iron chelator-nanoparticle conjugates as potential therapeutic agents for Alzheimer disease. <i>Progress in Brain Research</i> , 2009, 180, 97-108.	0.9	19
47	All- <i>trans</i> retinoic acid as a novel therapeutic strategy for Alzheimer's disease. <i>Expert Review of Neurotherapeutics</i> , 2009, 9, 1615-1621.	1.4	104
48	Amyloid- $\beta$ , Tau, and Dementia. <i>Journal of Alzheimer's Disease</i> , 2009, 17, 729-736.	1.2	53
49	Food Antioxidants and Alzheimer's Disease. <i>Oxidative Stress and Disease</i> , 2009, , .	0.3	0
50	Immunotherapy in a Natural Model of Alzheimer's Pathogenesis: The Aging Beagle. <i>CNS and Neurological Disorders - Drug Targets</i> , 2009, 8, 98-113.	0.8	12
51	MTDL Design Strategy in the Context of Alzheimer's Disease: From Lipocrine to Memoquin and Beyond. <i>Current Pharmaceutical Design</i> , 2009, 15, 601-613.	0.9	75
52	Increased Iron and Free Radical Generation in Preclinical Alzheimer Disease and Mild Cognitive Impairment. <i>Journal of Alzheimer's Disease</i> , 2010, 19, 363-372.	1.2	357
53	Reaching the Limits of Genome-wide Significance in Alzheimer Disease. <i>JAMA - Journal of the American Medical Association</i> , 2010, 303, 1864.	3.8	52
54	Inter-laboratory variation in cerebrospinal fluid biomarkers for Alzheimer's disease: united we stand, divided we fall. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 603-607.	1.4	78
55	Sirtuins and Aging. , 2010, , 51-75.		1
56	Insulin resistance is associated with the pathology of Alzheimer disease. <i>Neurology</i> , 2010, 75, 764-770.	1.5	382
57	Label-Free High-Throughput Screening Assay for Inhibitors of Alzheimer's Amyloid- $\beta$ Peptide Aggregation Based on MALDI MS. <i>Analytical Chemistry</i> , 2010, 82, 8558-8565.	3.2	31
58	DNA Methylation and Alzheimer's Disease. , 2010, , 315-326.		6

#	ARTICLE	IF	CITATIONS
59	A metabolomic study of the CRND8 transgenic mouse model of Alzheimer's disease. <i>Neurochemistry International</i> , 2010, 56, 937-947.	1.9	131
60	Analysis of three plasmid systems for use in DNA A $\beta$ 42 immunization as therapy for Alzheimer's disease. <i>Vaccine</i> , 2010, 28, 5280-5287.	1.7	30
61	Epigenetics of Aging. , 2010, , .		10
62	Association of Alzheimer disease pathology with abnormal lipid metabolism. <i>Neurology</i> , 2011, 77, 1068-1075.	1.5	92
64	Shift in brain metabolism in late onset Alzheimer's disease: Implications for biomarkers and therapeutic interventions. <i>Molecular Aspects of Medicine</i> , 2011, 32, 247-257.	2.7	99
65	Maturation of BRI2 generates a specific inhibitor that reduces APP processing at the plasma membrane and in endocytic vesicles. <i>Neurobiology of Aging</i> , 2011, 32, 1400-1408.	1.5	79
66	Introducing Human APOE into A $\beta$ 2 Transgenic Mouse Models. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-9.	1.1	42
67	Lipid Rafts: Linking Alzheimer's Amyloid- $\beta$ Production, Aggregation, and Toxicity at Neuronal Membranes. <i>International Journal of Alzheimer's Disease</i> , 2011, 2011, 1-14.	1.1	156
68	Phytic Acid as a Potential Treatment for Alzheimer's Pathology: Evidence from Animal and in vitro Models. <i>Journal of Alzheimer's Disease</i> , 2011, 23, 21-35.	1.2	62
69	Targeting Mitochondrial Bioenergetics for Alzheimers Prevention and Treatment. <i>Current Pharmaceutical Design</i> , 2011, 17, 3474-3479.	0.9	33
70	Solution NMR Studies of A $\beta$ 46; Monomer Dynamics. <i>Protein and Peptide Letters</i> , 2011, 18, 354-361.	0.4	8
71	The Mitochondrial Dynamics of Alzheimers Disease and Parkinsons Disease Offer Important Opportunities for Therapeutic Intervention. <i>Current Pharmaceutical Design</i> , 2011, 17, 3374-3380.	0.9	30
72	Neprilysin Protects against Cerebral Amyloid Angiopathy and A $\beta$ 42-Induced Degeneration of Cerebrovascular Smooth Muscle Cells. <i>Brain Pathology</i> , 2011, 21, 594-605.	2.1	38
73	Histologic study of age-related change in the posterior pituitary gland focusing on abnormal deposition of tau protein. <i>Pathology International</i> , 2011, 61, 13-18.	0.6	9
74	Daedalols A $\beta$ C, fungal-derived BACE1 inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2011, 19, 6581-6586.	1.4	13
75	Natural products as a source of Alzheimer's drug leads. <i>Natural Product Reports</i> , 2011, 28, 48-77.	5.2	340
76	Patterns of microRNA expression in normal and early Alzheimer's disease human temporal cortex: white matter versus gray matter. <i>Acta Neuropathologica</i> , 2011, 121, 193-205.	3.9	299
77	Demise of the Flies. <i>Progress in Molecular Biology and Translational Science</i> , 2011, 100, 483-498.	0.9	6

#	ARTICLE	IF	CITATIONS
78	Multitarget-Directed Ligands: Innovative Chemical Probes and Therapeutic Tools Against Alzheimer's Disease. <i>Current Topics in Medicinal Chemistry</i> , 2011, 11, 2797-2806.	1.0	35
79	Quantifying the Pathophysiological Timeline of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2011, 26, 745-753.	1.2	70
80	Treat Alzheimer Disease Before It Is Symptomatic. <i>Archives of Neurology</i> , 2011, 68, 1237.	4.9	7
81	Cerebrospinal Fluid Profiles and Prospective Course and Outcome in Patients With Amnesic Mild Cognitive Impairment. <i>Archives of Neurology</i> , 2011, 68, 113.	4.9	32
82	Nantenine as an acetylcholinesterase inhibitor: SAR, enzyme kinetics and molecular modeling investigations. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2011, 26, 46-55.	2.5	22
83	Alzheimer's disease models and functional genomics—How many needles are there in the haystack?. <i>Frontiers in Physiology</i> , 2012, 3, 320.	1.3	18
84	Alzheimer's Disease Biomarkers and Epigenetic Intermediates Following Exposure to Pb In Vitro. <i>Current Alzheimer Research</i> , 2012, 9, 555-562.	0.7	54
85	Protective Effect of Puerarin on $\beta$ -Amyloid-Induced Neurotoxicity in Rat Hippocampal Neurons. <i>Arzneimittelforschung</i> , 2012, 62, 187-193.	0.5	25
86	MicroRNAs as newer therapeutic targets: A big hope from a tiny player. <i>Journal of Pharmacology and Pharmacotherapeutics</i> , 2012, 3, 217.	0.2	30
87	Aging and Down Syndrome. <i>Current Gerontology and Geriatrics Research</i> , 2012, 2012, 1-6.	1.6	72
88	Correlation of Alzheimer Disease Neuropathologic Changes With Cognitive Status: A Review of the Literature. <i>Journal of Neuropathology and Experimental Neurology</i> , 2012, 71, 362-381.	0.9	1,599
89	Systemic and Central Immunity in Alzheimer's Disease: Therapeutic Implications. <i>CNS Neuroscience and Therapeutics</i> , 2012, 18, 64-76.	1.9	32
90	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2012, 8, S1-68.	0.4	432
91	NF- $\kappa$ B-regulated, proinflammatory miRNAs in Alzheimer's disease. <i>Alzheimer's Research and Therapy</i> , 2012, 4, 47.	3.0	68
92	Amyloid beta ( $A\beta$ ) peptide modulators and other current treatment strategies for Alzheimer's disease (AD). <i>Expert Opinion on Emerging Drugs</i> , 2012, 17, 43-60.	1.0	55
93	Amyloid- $\beta$ oligomers stimulate microglia through a tyrosine kinase dependent mechanism. <i>Neurobiology of Aging</i> , 2012, 33, 2247-2261.	1.5	93
94	Advances in the pathogenesis of Alzheimer's disease: a re-evaluation of amyloid cascade hypothesis. <i>Translational Neurodegeneration</i> , 2012, 1, 18.	3.6	94
95	Experimental Inhibition of Fibrillogenesis and Neurotoxicity by amyloid-beta ( $A\beta$ ) and Other Disease-Related Peptides/Proteins by Plant Extracts and Herbal Compounds. <i>Sub-Cellular Biochemistry</i> , 2012, 65, 295-326.	1.0	17

#	ARTICLE	IF	CITATIONS
96	MicroRNA 146a (miR-146a) Is Over-Expressed during Prion Disease and Modulates the Innate Immune Response and the Microglial Activation State. PLoS ONE, 2012, 7, e30832.	1.1	143
97	Estrogen Regulation of Mitochondrial Bioenergetics. Advances in Pharmacology, 2012, 64, 327-371.	1.2	70
98	Effect of bFGF on neuronal damage induced by sequential treatment of amyloid $\beta^2$ and excitatory amino acid in vitro and in vivo. European Journal of Pharmacology, 2012, 695, 76-82.	1.7	19
99	Apolipoprotein E Sets the Stage: Response to Injury Triggers Neuropathology. Neuron, 2012, 76, 871-885.	3.8	296
100	Dual Effect of Beta-Amyloid on $\alpha 7$ and $\alpha 4\beta 2$ Nicotinic Receptors Controlling the Release of Glutamate, Aspartate and GABA in Rat Hippocampus. PLoS ONE, 2012, 7, e29661.	1.1	59
101	Protein Tau: Prime Cause of Synaptic and Neuronal Degeneration in Alzheimer's Disease. International Journal of Alzheimer's Disease, 2012, 2012, 1-13.	1.1	45
102	Apolipoprotein E: Essential Catalyst of the Alzheimer Amyloid Cascade. International Journal of Alzheimer's Disease, 2012, 2012, 1-9.	1.1	67
103	Nanoparticle Delivery of Transition-Metal Chelators to the Brain: Oxidative Stress will Never See it Coming!. CNS and Neurological Disorders - Drug Targets, 2012, 11, 81-85.	0.8	35
104	Locus-specific mutation databases for neurodegenerative brain diseases. Human Mutation, 2012, 33, 1340-1344.	1.1	414
105	Cerebrospinal fluid biomarkers to monitor treatment effects in Alzheimer's disease and related conditions. Neurodegenerative Disease Management, 2012, 2, 117-123.	1.2	0
106	An expedient, ionic liquid mediated multi-component synthesis of novel piperidone grafted cholinesterase enzymes inhibitors and their molecular modeling study. European Journal of Medicinal Chemistry, 2013, 67, 221-229.	2.6	43
107	Microwave assisted synthesis, cholinesterase enzymes inhibitory activities and molecular docking studies of new pyridopyrimidine derivatives. Bioorganic and Medicinal Chemistry, 2013, 21, 3022-3031.	1.4	31
108	Use of biomarkers and imaging to assess pathophysiology, mechanisms of action and target engagement. Journal of Nutrition, Health and Aging, 2013, 17, 54-63.	1.5	28
109	Nanotechnology-Based Drug Delivery Systems for Targeting, Imaging and Diagnosis of Neurodegenerative Diseases. Pharmaceutical Research, 2013, 30, 2499-2511.	1.7	90
110	Microcontact printing of Alzheimer's $\beta^2$ -amyloid monomers and fibrils. European Polymer Journal, 2013, 49, 3052-3059.	2.6	1
111	Alzheimer disease therapy "moving from amyloid- $\beta^2$ to tau. Nature Reviews Neurology, 2013, 9, 677-686.	4.9	421
112	Design, Synthesis, and Biological Evaluation of 1-Phenylpyrazolo[3,4-e]pyrrolo[3,4-g]indolizine-4,6(1H,5H)-diones as New Glycogen Synthase Kinase-3 Inhibitors. Journal of Medicinal Chemistry, 2013, 56, 10066-10078.	2.9	39
113	The Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. Alzheimer's and Dementia, 2013, 9, e111-94.	0.4	535

#	ARTICLE	IF	CITATIONS
114	Review: Systemic inflammation and Alzheimer's disease. <i>Neurobiology and Applied Neurobiology</i> , 2013, 39, 51-68.	1.8	282
115	Advances with RNA interference in Alzheimer's disease research. <i>Drug Design, Development and Therapy</i> , 2013, 7, 117.	2.0	20
116	Levels of Soluble Apolipoprotein E/Amyloid- $\beta^2$ (A $\beta^2$ ) Complex Are Reduced and Oligomeric A $\beta^2$ Increased with APOE4 and Alzheimer Disease in a Transgenic Mouse Model and Human Samples*. <i>Journal of Biological Chemistry</i> , 2013, 288, 5914-5926.	1.6	136
117	Studying micro RNA Function and Dysfunction in Alzheimer's Disease. <i>Frontiers in Genetics</i> , 2012, 3, 327.	1.1	65
118	Intraneuronal tau aggregation precedes diffuse plaque deposition, but amyloid- $\beta^2$ changes occur before increases of tau in cerebrospinal fluid. <i>Acta Neuropathologica</i> , 2013, 126, 631-641.	3.9	125
119	Swedish mutant APP suppresses osteoblast differentiation and causes osteoporotic deficit, which are ameliorated by N-acetyl-L-cysteine. <i>Journal of Bone and Mineral Research</i> , 2013, 28, 2122-2135.	3.1	54
120	Oxidative Stress Induces Apolipoprotein D Overexpression in Hippocampus during Aging and Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2013, 36, 129-144.	1.2	33
121	Anti-amyloid-beta to tau-based immunization: developments in immunotherapy for Alzheimer's disease. <i>ImmunoTargets and Therapy</i> , 2013, 2013, 105.	2.7	32
122	Mitotic Spindle Defects and Chromosome Mis-Segregation Induced by LDL/Cholesterol Implications for Niemann-Pick C1, Alzheimer's Disease, and Atherosclerosis. <i>PLoS ONE</i> , 2013, 8, e60718.	1.1	29
123	A Structure-Toxicity Study of A $\beta$ 42 Reveals a New Anti-Parallel Aggregation Pathway. <i>PLoS ONE</i> , 2013, 8, e80262.	1.1	41
124	What Renders TAU Toxic. <i>Frontiers in Neurology</i> , 2013, 4, 72.	1.1	67
125	P-Glycoprotein Altered Expression in Alzheimer's Disease: Regional Anatomic Variability. <i>Journal of Neurodegenerative Diseases</i> , 2013, 2013, 1-7.	1.1	8
126	Computational Design of Apolipoprotein E4 Inhibitors for Alzheimer's Disease Therapy from Traditional Chinese Medicine. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	11
127	Resveratrol as a Therapeutic Agent for Alzheimer's Disease. <i>BioMed Research International</i> , 2014, 2014, 1-13.	0.9	97
128	Prevention approaches in a preclinical canine model of Alzheimer's disease: benefits and challenges. <i>Frontiers in Pharmacology</i> , 2014, 5, 47.	1.6	32
129	Effect of the beta secretase-1 inhibitor on the amyloid C-terminal fragment of amyloid precursor protein processing in a hyperphosphorylated tau rat model. <i>Genetics and Molecular Research</i> , 2014, 13, 6213-6227.	0.3	2
130	Cerebrovascular Pathology and Amyloid Plaque Formation in Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2014, 11, 4-10.	0.7	26
131	SUN11602 has basic fibroblast growth factor-like activity and attenuates neuronal damage and cognitive deficits in a rat model of Alzheimer's disease induced by amyloid $\beta^2$ and excitatory amino acids. <i>Brain Research</i> , 2014, 1585, 159-166.	1.1	11



#	ARTICLE	IF	CITATIONS
132	Blocking the apolipoprotein E/Amyloid $\beta$ interaction in triple transgenic mice ameliorates Alzheimer's disease related amyloid $\beta$ and tau pathology. <i>Journal of Neurochemistry</i> , 2014, 128, 577-591.	2.1	50
133	Upregulation of miR-181 Decreases c-Fos and SIRT-1 in the Hippocampus of 3xTg-AD Mice. <i>Journal of Alzheimer's Disease</i> , 2014, 42, 1229-1238.	1.2	77
134	Alzheimer's disease: The role for neurosurgery. , 2014, 5, 385.		10
135	Reciprocal disruption of neuronal signaling and $A\beta$ production mediated by extrasynaptic NMDA receptors: a downward spiral. <i>Cell and Tissue Research</i> , 2014, 356, 279-286.	1.5	40
136	Soluble apoE/ $A\beta$ complex: mechanism and therapeutic target for APOE4-induced AD risk. <i>Molecular Neurodegeneration</i> , 2014, 9, 2.	4.4	98
137	Fluorinated benzophenone derivatives: Balanced multipotent agents for Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2014, 78, 157-166.	2.6	21
138	A label-free electrical impedimetric biosensor for the specific detection of Alzheimer's amyloid-beta oligomers. <i>Biosensors and Bioelectronics</i> , 2014, 56, 83-90.	5.3	166
139	Aging in the Canine and Feline Brain. <i>Veterinary Clinics of North America - Small Animal Practice</i> , 2014, 44, 1113-1129.	0.5	50
140	Signaling pathway cross talk in Alzheimer's disease. <i>Cell Communication and Signaling</i> , 2014, 12, 23.	2.7	126
141	Chronic Aluminum Intake Causes Alzheimer's Disease: Applying Sir Austin Bradford Hill's Causality Criteria. <i>Journal of Alzheimer's Disease</i> , 2014, 40, 765-838.	1.2	97
142	Spongiapyridine and Related Spongians Isolated from an Indonesian <i>Spongia</i> sp.. <i>Journal of Natural Products</i> , 2014, 77, 1644-1649.	1.5	14
143	Phosphorylation of Ser8 promotes zinc-induced dimerization of the amyloid- $\beta$ metal-binding domain. <i>Molecular BioSystems</i> , 2014, 10, 2590-2596.	2.9	49
144	Advances in recent patent and clinical trial drug development for Alzheimer's disease. <i>Pharmaceutical Patent Analyst</i> , 2014, 3, 429-447.	0.4	19
145	Temsirolimus promotes autophagic clearance of amyloid- $\beta$ and provides protective effects in cellular and animal models of Alzheimer's disease. <i>Pharmacological Research</i> , 2014, 81, 54-63.	3.1	157
146	Iron overload accelerates neuronal amyloid- $\beta$ production and cognitive impairment in transgenic mice model of Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 2288-2301.	1.5	106
147	Cholinergic basal forebrain atrophy predicts amyloid burden in Alzheimer's disease. <i>Neurobiology of Aging</i> , 2014, 35, 482-491.	1.5	94
148	March separate, strike together – Role of phosphorylated TAU in mitochondrial dysfunction in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Molecular Basis of Disease</i> , 2014, 1842, 1258-1266.	1.8	92
149	Identification of early-stage Alzheimer's disease using SFAM neural network. <i>Neurocomputing</i> , 2014, 143, 170-181.	3.5	5

#	ARTICLE	IF	CITATIONS
150	Gamma-Secretase Inhibitor Activity of a <i>Pterocarpus erinaceus</i> Extract. <i>Neurodegenerative Diseases</i> , 2014, 14, 39-51.	0.8	12
151	Anti-Amyloidogenic Properties of <i>Dioscorea</i> <i>Dioscorea</i> Crassirhizoma</i> Roots in Alzheimer's Disease Cellular Model. <i>Journal of Food Biochemistry</i> , 2015, 39, 478-484.	1.2	3
152	Mouse brain magnetic resonance microscopy: Applications in <sup>A</sup> Alzheimer disease. <i>Microscopy Research and Technique</i> , 2015, 78, 416-424.	1.2	9
153	Role of Hybrid Brain Imaging in Neuropsychiatric Disorders. <i>Diagnostics</i> , 2015, 5, 577-614.	1.3	11
154	Menopause, obesity and inflammation: interactive risk factors for Alzheimer's disease. <i>Frontiers in Aging Neuroscience</i> , 2015, 7, 130.	1.7	81
155	Preventing Effect of L-Type Calcium Channel Blockade on Electrophysiological Alterations in Dentate Gyrus Granule Cells Induced by Entorhinal Amyloid Pathology. <i>PLoS ONE</i> , 2015, 10, e0117555.	1.1	21
156	Structure-Based Peptide Design to Modulate Amyloid Beta Aggregation and Reduce Cytotoxicity. <i>PLoS ONE</i> , 2015, 10, e0129087.	1.1	37
157	Iron Chelation Inhibits Osteoclastic Differentiation In Vitro and in Tg2576 Mouse Model of Alzheimer's Disease. <i>PLoS ONE</i> , 2015, 10, e0139395.	1.1	18
158	Serotonin 6 receptor controls Alzheimer's disease and depression. <i>Oncotarget</i> , 2015, 6, 26716-26728.	0.8	45
159	Role of Trisomy 21 Mosaicism in Sporadic and Familial Alzheimer's Disease. <i>Current Alzheimer Research</i> , 2015, 13, 7-17.	0.7	40
160	The synthesis and evaluation of near-infrared probes with barbituric acid acceptors for <i>in vivo</i> detection of amyloid plaques. <i>Chemical Communications</i> , 2015, 51, 11665-11668.	2.2	38
161	Temperature and toxic Tau in Alzheimer's disease: new insights. <i>Temperature</i> , 2015, 2, 491-498.	1.7	29
162	The Voltage-dependent Anion Channel 1 Mediates Amyloid $\beta^2$ Toxicity and Represents a Potential Target for Alzheimer Disease Therapy. <i>Journal of Biological Chemistry</i> , 2015, 290, 30670-30683.	1.6	109
163	Preventing Alzheimer's disease by means of natural selection. <i>Journal of the Royal Society Interface</i> , 2015, 12, 20140919.	1.5	21
164	Purification, characterization and neuroprotective effects of a polysaccharide from <i>Gynostemma pentaphyllum</i> . <i>Carbohydrate Polymers</i> , 2015, 122, 93-100.	5.1	38
165	<sup>A</sup> modulated $A\beta$ -induced neuroinflammation in Alzheimer's disease: current landscape, novel data, and future perspective. <i>Journal of Neurochemistry</i> , 2015, 133, 465-488.	2.1	123
166	Explorative and targeted neuroproteomics in Alzheimer's disease. <i>Biochimica Et Biophysica Acta - Proteins and Proteomics</i> , 2015, 1854, 769-778.	1.1	41
167	Enfermedad de Alzheimer. <i>Medicine</i> , 2015, 11, 4306-4315.	0.0	4

#	ARTICLE	IF	CITATIONS
168	2014 Update of the Alzheimer's Disease Neuroimaging Initiative: A review of papers published since its inception. <i>Alzheimer's and Dementia</i> , 2015, 11, e1-120.	0.4	261
169	Glucose regulates amyloid $\beta$ production via AMPK. <i>Journal of Neural Transmission</i> , 2015, 122, 1381-1390.	1.4	11
170	Access to 2-(Het)aryl and 2-Styryl Benzoxazoles via Palladium-Catalyzed Aminocarbonylation of Aryl and Vinyl Bromides. <i>Organic Letters</i> , 2015, 17, 2094-2097.	2.4	34
171	Exploring the Alzheimer amyloid- $\beta$ peptide conformational ensemble: A review of molecular dynamics approaches. <i>Peptides</i> , 2015, 69, 86-91.	1.2	69
172	Does the difference between PART and Alzheimer's disease lie in the age-related changes in cerebral arteries that trigger the accumulation of $A\beta$ and propagation of tau?. <i>Acta Neuropathologica</i> , 2015, 129, 763-766.	3.9	37
173	Recent imaging advances in neurology. <i>Journal of Neurology</i> , 2015, 262, 2182-2194.	1.8	33
174	Dual functional cholinesterase and MAO inhibitors for the treatment of Alzheimer's disease: synthesis, pharmacological analysis and molecular modeling of homoisoflavonoid derivatives. <i>Journal of Enzyme Inhibition and Medicinal Chemistry</i> , 2015, 31, 1-9.	2.5	34
175	Bamboo leaf extract improves spatial learning ability in a rat model with senile dementia. <i>Journal of Zhejiang University: Science B</i> , 2015, 16, 593-601.	1.3	14
176	Orientin alleviates cognitive deficits and oxidative stress in $A\beta$ 42-induced mouse model of Alzheimer's disease. <i>Life Sciences</i> , 2015, 121, 104-109.	2.0	90
177	Neuroanatomy and Pathology of Sporadic Alzheimer's Disease. <i>Advances in Anatomy, Embryology and Cell Biology</i> , 2015, , .	1.0	81
178	The Potential Effect of Caffeine and Nicotine Co-administration against Aluminum-induced Alzheimer's disease in Rats. , 2016, 6, .		2
179	Blood-based Amyloid and Tau Biomarker Tests For Alzheimer's Disease. <i>Neuroscience and Biomedical Engineering</i> , 2016, 4, 4-13.	0.4	0
180	Naturally Inspired Molecules as Multifunctional Agents for Alzheimer's Disease Treatment. <i>Molecules</i> , 2016, 21, 643.	1.7	14
181	Peptides as Recognition Molecules and Therapeutic Agents. <i>Chemical Record</i> , 2016, 16, 1772-1786.	2.9	48
182	Design, synthesis and cholinesterase inhibitory evaluation study of fluorescent N-benzylpiperidine-4-one derivatives. <i>Medicinal Chemistry Research</i> , 2016, 25, 1705-1715.	1.1	5
183	Optically Pure Diphenoxy Derivatives as More Flexible Probes for $\beta$ -Amyloid Plaques. <i>ACS Chemical Neuroscience</i> , 2016, 7, 1275-1282.	1.7	4
184	Ten Challenges of the Amyloid Hypothesis of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2016, 55, 447-457.	1.2	71
185	A human carboxypeptidase E/NF- $\kappa$ B1 gene mutation in an Alzheimer's disease patient leads to dementia and depression in mice. <i>Translational Psychiatry</i> , 2016, 6, e973-e973.	2.4	22

#	ARTICLE	IF	CITATIONS
186	Synthesis and biological evaluation of new spirooxindoles with embedded pharmacophores. <i>New Journal of Chemistry</i> , 2016, 40, 5164-5169.	1.4	38
187	DYRK1A inhibition as potential treatment for Alzheimer's disease. <i>Future Medicinal Chemistry</i> , 2016, 8, 681-696.	1.1	58
188	G-protein coupled receptors as therapeutic targets for neurodegenerative and cerebrovascular diseases. <i>Neurochemistry International</i> , 2016, 101, 1-14.	1.9	28
189	Selenomethionine reduces the deposition of beta-amyloid plaques by modulating $\beta$ -secretase and enhancing selenoenzymatic activity in a mouse model of Alzheimer's disease. <i>Metallomics</i> , 2016, 8, 782-789.	1.0	28
190	Inhibition of Wnt signaling induces amyloidogenic processing of amyloid precursor protein and the production and aggregation of Amyloid- $\beta$ (A $\beta$ ) <sub>42</sub> peptides. <i>Journal of Neurochemistry</i> , 2016, 139, 1175-1191.	2.1	62
191	Alzheimer's disease due to loss of function: A new synthesis of the available data. <i>Progress in Neurobiology</i> , 2016, 143, 36-60.	2.8	111
192	Cassia obtusifolia seed ameliorates amyloid $\beta$ -induced synaptic dysfunction through anti-inflammatory and Akt/GSK-3 $\beta$ pathways. <i>Journal of Ethnopharmacology</i> , 2016, 178, 50-57.	2.0	40
193	Neurodegeneration and Alzheimer's disease (AD). What Can Proteomics Tell Us About the Alzheimer's Brain?. <i>Molecular and Cellular Proteomics</i> , 2016, 15, 409-425.	2.5	79
194	Diseases in the Elderly. , 2016, , .		3
195	Vascular and Metabolic Factors in Alzheimer's Disease and Related Dementias: Introduction. <i>Cellular and Molecular Neurobiology</i> , 2016, 36, 151-154.	1.7	42
196	Long-term exposure to ELF-MF ameliorates cognitive deficits and attenuates tau hyperphosphorylation in 3xTg AD mice. <i>NeuroToxicology</i> , 2016, 53, 290-300.	1.4	14
197	Discovery of Isonicotinamides as Highly Selective, Brain Penetrable, and Orally Active Glycogen Synthase Kinase-3 Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2016, 59, 1041-1051.	2.9	47
198	Do anti-amyloid beta protein antibody cross reactivities confound Alzheimer disease research?. <i>Journal of Negative Results in BioMedicine</i> , 2017, 16, 1.	1.4	51
200	Mitochondrial Aspects of Synaptic Dysfunction in Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2017, 57, 1087-1103.	1.2	176
201	Design and synthesis of new piperidone grafted acetylcholinesterase inhibitors. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 228-231.	1.0	23
202	Evolving Relevance of Neuroproteomics in Alzheimer's Disease. <i>Methods in Molecular Biology</i> , 2017, 1598, 101-115.	0.4	14
203	Alzheimer's disease: How metal ions define $\beta$ -amyloid function. <i>Coordination Chemistry Reviews</i> , 2017, 351, 127-159.	9.5	120
204	Recent progress in the development of metal complexes as $\beta$ -amyloid imaging probes in the brain. <i>MedChemComm</i> , 2017, 8, 1393-1407.	3.5	36

#	ARTICLE	IF	CITATIONS
205	Recent progress on curcumin-based therapeutics: a patent review (2012-2016). Part II: curcumin derivatives in cancer and neurodegeneration. <i>Expert Opinion on Therapeutic Patents</i> , 2017, 27, 953-965.	2.4	30
206	Gene-gene interaction between PPARC and APOE gene on late-onset Alzheimer's disease: A case-control study in Chinese han population. <i>Journal of Nutrition, Health and Aging</i> , 2017, 21, 397-403.	1.5	12
207	Pyroglutamate $\beta$ -amyloid- $\beta$ peptide expression in <i>Drosophila</i> leads to caspase-dependent and endoplasmic reticulum stress $\beta$ -related progressive neurodegeneration. <i>Human Molecular Genetics</i> , 2017, 26, 4642-4656.	1.4	5
208	Flavonoids and their derivatives with $\beta$ -amyloid aggregation inhibitory activity from the leaves and twigs of <i>Pithecellobium clypearia</i> Benth. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2017, 27, 4823-4827.	1.0	13
209	Single-Molecule Fluorescence Resonance Energy Transfer Studies of $\beta$ -Amyloid Clusters in Physiological Solutions. <i>World Scientific Lecture and Course Notes in Chemistry</i> , 2017, , 297-311.	0.2	0
210	Ethanol extract of <i>Sophora japonica</i> flower buds alleviates cognitive deficits induced by scopolamine in mice. <i>Oriental Pharmacy and Experimental Medicine</i> , 2017, 17, 337-344.	1.2	7
211	Endothelial LRP1 $\beta$ A Potential Target for the Treatment of Alzheimer $\beta$ 's Disease. <i>Pharmaceutical Research</i> , 2017, 34, 2637-2651.	1.7	43
212	Review: Neuropathology and behavioural features of transgenic murine models of Alzheimer's disease. <i>Neuropathology and Applied Neurobiology</i> , 2017, 43, 553-570.	1.8	46
213	Group-Level Progressive Alterations in Brain Connectivity Patterns Revealed by Diffusion-Tensor Brain Networks across Severity Stages in Alzheimer $\beta$ 's Disease. <i>Frontiers in Aging Neuroscience</i> , 2017, 9, 215.	1.7	34
214	Localized vs. Systematic Neurodegeneration: A Paradigm Shift in Understanding Neurodegenerative Diseases. <i>Frontiers in Systems Neuroscience</i> , 2017, 11, 62.	1.2	9
215	Production of an anti-A $\beta$ antibody fragment in <i>Pichia pastoris</i> and in vitro and in vivo validation of its therapeutic effect. <i>PLoS ONE</i> , 2017, 12, e0181480.	1.1	25
216	Multivariate regression analysis of structural MRI connectivity matrices in Alzheimer $\beta$ 's disease. <i>PLoS ONE</i> , 2017, 12, e0187281.	1.1	15
217	Neurochemical Aspects of $\beta$ -Amyloid Cascade Hypothesis for Alzheimer $\beta$ 's Disease. , 2017, , 1-46.		0
218	Synaptic vesicle cycle and amyloid $\beta$ : Biting the hand that feeds. <i>Alzheimer's and Dementia</i> , 2018, 14, 502-513.	0.4	40
219	Factors influencing accuracy of cortical thickness in the diagnosis of Alzheimer's disease. <i>Human Brain Mapping</i> , 2018, 39, 1500-1515.	1.9	21
220	The Amygdala as a Locus of Pathologic Misfolding in Neurodegenerative Diseases. <i>Journal of Neuropathology and Experimental Neurology</i> , 2018, 77, 2-20.	0.9	77
221	Down syndrome, beta-amyloid and neuroimaging. <i>Free Radical Biology and Medicine</i> , 2018, 114, 102-109.	1.3	28
222	Discovery of novel propargylamine-modified 4-aminoalkyl imidazole substituted pyrimidinylthiourea derivatives as multifunctional agents for the treatment of Alzheimer's disease. <i>European Journal of Medicinal Chemistry</i> , 2018, 143, 33-47.	2.6	60

#	ARTICLE	IF	CITATIONS
223	Wnt signaling loss accelerates the appearance of neuropathological hallmarks of Alzheimer's disease in J20 $\beta$ APP transgenic and wild-type mice. <i>Journal of Neurochemistry</i> , 2018, 144, 443-465.	2.1	66
224	Synthesis of novel hydroxyspiro[indoline-3,9 $\beta$ -xanthene]trione derivatives using solid acids as catalyst. <i>Monatshefte für Chemie</i> , 2018, 149, 73-85.	0.9	5
225	Autophagy impairment by caspase-1 dependent inflammation mediates memory loss in response to $\beta$ -Amyloid peptide accumulation. <i>Journal of Neuroscience Research</i> , 2018, 96, 234-246.	1.3	30
226	The Blood brain-barrier and its role in Alzheimer's disease. <i>Neuroforum</i> , 2018, 24, A197-A205.	0.2	13
227	Die Blut-Hirn-Schranke und ihre Rolle in der Alzheimer's Krankheit. <i>Neuroforum</i> , 2018, 24, 287-296.	0.2	0
228	Diagnostic utility of positron emission tomography-computed tomography and indications for 18F-Fluorodeoxyglucose and amyloid-tracers. <i>Geriatric Care</i> , 2018, 4, .	0.2	0
229	A $\beta$ 42/A $\beta$ 40 Ratios of Presenilin 1 Mutations Correlate with Clinical Onset of Alzheimer's Disease. <i>Journal of Alzheimer's Disease</i> , 2018, 66, 939-945.	1.2	37
230	Label-free imaging of amyloid plaques in Alzheimer's disease with stimulated Raman scattering microscopy. <i>Science Advances</i> , 2018, 4, eaat7715.	4.7	122
231	Chronic noise exposure exacerbates AD-like neuropathology in SAMP8 mice in relation to Wnt signaling in the PFC and hippocampus. <i>Scientific Reports</i> , 2018, 8, 14622.	1.6	17
232	Zebrafish: an emerging real-time model system to study Alzheimer's disease and neurospecific drug discovery. <i>Cell Death Discovery</i> , 2018, 4, 45.	2.0	129
233	APP promotes osteoblast survival and bone formation by regulating mitochondrial function and preventing oxidative stress. <i>Cell Death and Disease</i> , 2018, 9, 1077.	2.7	29
234	Protein nitration profile of CD3+ lymphocytes from Alzheimer disease patients: Novel hints on immunosenescence and biomarker detection. <i>Free Radical Biology and Medicine</i> , 2018, 129, 430-439.	1.3	20
235	Classification of Alzheimer's and MCI Patients from Semantically Parcelled PET Images: A Comparison between AV45 and FDG-PET. <i>International Journal of Biomedical Imaging</i> , 2018, 2018, 1-13.	3.0	49
236	In Vivo Near-Infrared Two-Photon Imaging of Amyloid Plaques in Deep Brain of Alzheimer's Disease Mouse Model. <i>ACS Chemical Neuroscience</i> , 2018, 9, 3128-3136.	1.7	50
237	Diffuse Amyloid- $\beta$ Plaques, Neurofibrillary Tangles, and the Impact of APOE in Elderly Persons' Brains Lacking Neuritic Amyloid Plaques. <i>Journal of Alzheimer's Disease</i> , 2018, 64, 1307-1324.	1.2	34
238	The concerted amyloid-beta clearance of LRP1 and ABCB1/P-gp across the blood-brain barrier is linked by PICALM. <i>Brain, Behavior, and Immunity</i> , 2018, 73, 21-33.	2.0	86
239	In Search of an Identity for Amyloid Plaques. <i>Trends in Neurosciences</i> , 2018, 41, 483-486.	4.2	12
240	Differential effects of apoE and apoJ mimetic peptides on the action of an anti-A $\beta$ scFv in 3xTg-AD mice. <i>Biochemical Pharmacology</i> , 2018, 155, 380-392.	2.0	17

#	ARTICLE	IF	CITATIONS
241	Novel Scaffolds for Dual Specificity Tyrosine-Phosphorylation-Regulated Kinase (DYRK1A) Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2018, 61, 7560-7572.	2.9	26
242	Structure-Property Relationships of Polyethylene Glycol Modified Fluorophore as Near-Infrared A $\beta$ Imaging Probes. <i>Analytical Chemistry</i> , 2018, 90, 8576-8582.	3.2	22
243	Metal Binding to Amyloid- $\beta$ : A Ligand Field Molecular Dynamics Study. <i>ACS Chemical Neuroscience</i> , 2018, 9, 2795-2806.	1.7	19
244	The Dog as a Model for Aging Research. , 2018, , 167-176.		2
245	The development of a stochastic mathematical model of Alzheimer's disease to help improve the design of clinical trials of potential treatments. <i>PLoS ONE</i> , 2018, 13, e0190615.	1.1	26
246	Blood-Brain Barrier: Physiological and Functional Considerations. , 2018, , 229-236.		3
247	A Large Panel of Isogenic APP and PSEN1 Mutant Human iPSC Neurons Reveals Shared Endosomal Abnormalities Mediated by APP $\beta$ -CTFs, Not A $\beta$ . <i>Neuron</i> , 2019, 104, 256-270.e5.	3.8	185
248	Targeting the Interaction Between Apolipoprotein E and Amyloid Precursor Protein: A Novel Alzheimer's Disease Therapy. <i>Biological Psychiatry</i> , 2019, 86, 169-170.	0.7	2
249	Copper imbalance in Alzheimer's disease: Convergence of the chemistry and the clinic. <i>Coordination Chemistry Reviews</i> , 2019, 397, 168-187.	9.5	65
250	Current and emerging avenues for Alzheimer's disease drug targets. <i>Journal of Internal Medicine</i> , 2019, 286, 398-437.	2.7	102
251	Baicalein suppresses Repeat Tau fibrillization by sequestering oligomers. <i>Archives of Biochemistry and Biophysics</i> , 2019, 675, 108119.	1.4	47
252	Computational analysis of Alzheimer-causing mutations in amyloid precursor protein and presenilin 1. <i>Archives of Biochemistry and Biophysics</i> , 2019, 678, 108168.	1.4	13
253	Cell size effects in the molecular dynamics of the intrinsically disordered A $\beta$ peptide. <i>Journal of Chemical Physics</i> , 2019, 151, 085101.	1.2	17
254	Autophagy alleviates the decrease in proliferation of amyloid $\beta$ -treated bone marrow mesenchymal stem cells via the AKT/mTOR signaling pathway. <i>Molecular Medicine Reports</i> , 2019, 19, 4091-4100.	1.1	9
255	Tau and mTOR: The Hotspots for Multifarious Diseases in Alzheimer's Development. <i>Frontiers in Neuroscience</i> , 2018, 12, 1017.	1.4	65
256	Computing the Pathogenicity of Alzheimer's Disease Presenilin 1 Mutations. <i>Journal of Chemical Information and Modeling</i> , 2019, 59, 858-870.	2.5	19
257	Aging, lifestyle and dementia. <i>Neurobiology of Disease</i> , 2019, 130, 104481.	2.1	97
258	Adiponectin suppresses amyloid- $\beta$ oligomer (A $\beta$ O)-induced inflammatory response of microglia via AdipoR1-AMPK-NF- $\kappa$ B signaling pathway. <i>Journal of Neuroinflammation</i> , 2019, 16, 110.	3.1	78

#	ARTICLE	IF	CITATIONS
259	Molecular dynamics simulation of aluminium binding to amyloid- $\beta^2$ and its effect on peptide structure. PLoS ONE, 2019, 14, e0217992.	1.1	23
260	A quantitative model of human neurodegenerative diseases involving protein aggregation. Neurobiology of Aging, 2019, 80, 46-55.	1.5	23
261	Dispiropyrrolidinyl-piperidone embedded indeno[1,2-b]quinoxaline heterocyclic hybrids: Synthesis, cholinesterase inhibitory activity and their molecular docking simulation. Bioorganic and Medicinal Chemistry, 2019, 27, 2621-2628.	1.4	38
262	Connectome-wide network analysis of white matter connectivity in Alzheimer's disease. NeuroImage: Clinical, 2019, 22, 101690.	1.4	24
263	Tau and TDP-43 proteinopathies: kindred pathologic cascades and genetic pleiotropy. Laboratory Investigation, 2019, 99, 993-1007.	1.7	60
264	The Role of Apolipoprotein E Isoforms in Alzheimer's Disease. Journal of Alzheimer's Disease, 2019, 68, 459-471.	1.2	21
265	The amyloid cascade and Alzheimer's disease therapeutics: theory versus observation. Laboratory Investigation, 2019, 99, 958-970.	1.7	82
266	Dementia spectrum disorders: lessons learnt from decades with PET research. Journal of Neural Transmission, 2019, 126, 233-251.	1.4	32
267	Replica exchange molecular dynamics simulation of the coordination of Pt(II)-Phenanthroline to amyloid- $\beta^2$ . RSC Advances, 2019, 9, 35089-35097.	1.7	5
268	Resveratrol: from enhanced biosynthesis and bioavailability to multitargeting chronic diseases. Biomedicine and Pharmacotherapy, 2019, 109, 2237-2251.	2.5	144
269	Ameliorative effect of alendronate against intracerebroventricular streptozotocin induced alteration in neurobehavioral, neuroinflammation and biochemical parameters with emphasis on $A\beta^2$ and BACE-1. NeuroToxicology, 2019, 70, 122-134.	1.4	28
270	Nanocomposites Inhibit the Formation, Mitigate the Neurotoxicity, and Facilitate the Removal of $\beta^2$ -Amyloid Aggregates in Alzheimer's Disease Mice. Nano Letters, 2019, 19, 674-683.	4.5	124
271	Understanding disease progression and improving Alzheimer's disease clinical trials: Recent highlights from the Alzheimer's Disease Neuroimaging Initiative. Alzheimer's and Dementia, 2019, 15, 106-152.	0.4	302
272	The rare and the common: scale and the genetic imaginary in Alzheimer's disease drug development. New Genetics and Society, 2020, 39, 101-126.	0.7	8
273	Sarsapogenin: A steroidal saponin from <i>Asparagus racemosus</i> as multi target directed ligand in Alzheimer's disease. Steroids, 2020, 153, 108529.	0.8	44
274	Scopoletin: Anti-amyloidogenic, Anticholinesterase, and Neuroprotective Potential of a Natural Compound Present in <i>Argyrea speciosa</i> Roots by In Vitro and In Silico Study. Neuroscience Insights, 2020, 15, 263310552093769.	0.9	24
275	TMEM59 Haploinsufficiency Ameliorates the Pathology and Cognitive Impairment in the 5xFAD Mouse Model of Alzheimer's Disease. Frontiers in Cell and Developmental Biology, 2020, 8, 596030.	1.8	9
276	Biophysical, Biochemical, and Behavioral Implications of ApoE3 Conjugated Donepezil Nanomedicine in a $A\beta^{1-42}$ Induced Alzheimer's Disease Rat Model. ACS Chemical Neuroscience, 2020, 11, 4139-4151.	1.7	22



#	ARTICLE	IF	CITATIONS
277	Identification of Structural Calcium Binding Sites in Membrane-Bound Presenilin 1 and 2. <i>Journal of Physical Chemistry B</i> , 2020, 124, 4697-4711.	1.2	6
278	Neuroprotective role of alendronate against APP processing and neuroinflammation in mice fed a high fat diet. <i>Brain Research Bulletin</i> , 2020, 161, 197-212.	1.4	15
280	Insulin resistance and Alzheimer's disease. , 2020, , 249-292.		1
281	Cholesterol and Alzheimer's Disease Risk: A Meta-Analysis. <i>Brain Sciences</i> , 2020, 10, 386.	1.1	72
282	A Unique GSK-3 $\beta$ inhibitor B10 Has a Direct Effect on A $\beta$ <sup>2</sup> , Targets Tau and Metal Dyshomeostasis, and Promotes Neuronal Neurite Outgrowth. <i>Cells</i> , 2020, 9, 649.	1.8	17
283	Cellular senescence and Alzheimer disease: the egg and the chicken scenario. <i>Nature Reviews Neuroscience</i> , 2020, 21, 433-444.	4.9	132
284	Mini Review: Opposing Pathologies in Cancer and Alzheimer's Disease: Does the PI3K/Akt Pathway Provide Clues?. <i>Frontiers in Endocrinology</i> , 2020, 11, 403.	1.5	14
285	Half a century of amyloids: past, present and future. <i>Chemical Society Reviews</i> , 2020, 49, 5473-5509.	18.7	345
286	Inhibitory effects of curcumin on H <sub>2</sub> O <sub>2</sub> -induced cell damage and APP expression and processing in SH-SY5Y cells transfected with APP gene with Swedish mutation. <i>Molecular Biology Reports</i> , 2020, 47, 2047-2059.	1.0	9
287	Interaction of A $\beta$ <sup>242</sup> with Membranes Triggers the Self-Assembly into Oligomers. <i>International Journal of Molecular Sciences</i> , 2020, 21, 1129.	1.8	29
288	Low and High Molecular Weight FGF-2 Have Differential Effects on Astrocyte Proliferation, but Are Both Protective Against A $\beta$ <sup>2</sup> -Induced Cytotoxicity. <i>Frontiers in Molecular Neuroscience</i> , 2019, 12, 328.	1.4	19
289	Salivary Biomarkers: Future Approaches for Early Diagnosis of Neurodegenerative Diseases. <i>Brain Sciences</i> , 2020, 10, 245.	1.1	25
290	Ajmalicine and Reserpine: Indole Alkaloids as Multi-Target Directed Ligands Towards Factors Implicated in Alzheimer's Disease. <i>Molecules</i> , 2020, 25, 1609.	1.7	26
291	Multi-scale graph-based grading for Alzheimer's disease prediction. <i>Medical Image Analysis</i> , 2021, 67, 101850.	7.0	28
292	Amyloid Beta. , 2021, , 1-17.		0
293	Alterations and Associations Between Magnetic Susceptibility of the Basal Ganglia and Diffusion Properties in Alzheimer's Disease. <i>Frontiers in Neuroscience</i> , 2021, 15, 616163.	1.4	2
294	Effect of reductions in amyloid levels on cognitive change in randomized trials: instrumental variable meta-analysis. <i>BMJ, The</i> , 2021, 372, n156.	3.0	113
295	Prognostic Role of CSF A $\beta$ <sup>42</sup> /A $\beta$ <sup>40</sup> Ratio in Patients Affected by Amyotrophic Lateral Sclerosis. <i>Brain Sciences</i> , 2021, 11, 302.	1.1	8

#	ARTICLE	IF	CITATIONS
296	Anti-A $\beta$ -scFv-loaded polymeric nano-micelles with enhanced plasma stability. <i>Journal of Pharmacy and Pharmacology</i> , 2021, 73, 460-472.	1.2	1
297	Activation of CREB-mediated autophagy by thioperamide ameliorates $\beta$ -amyloid pathology and cognition in Alzheimer's disease. <i>Aging Cell</i> , 2021, 20, e13333.	3.0	24
298	siRNA Therapeutics: Future Promise for Neurodegenerative Diseases. <i>Current Neuropharmacology</i> , 2021, 19, 1896-1911.	1.4	10
300	Multi-Target-Directed Ligands as an Effective Strategy for the Treatment of Alzheimer's Disease. <i>Current Medicinal Chemistry</i> , 2022, 29, 1757-1803.	1.2	12
301	Characterization of monomeric and soluble aggregated A $\beta$ in Down's syndrome and Alzheimer's disease brains. <i>Neuroscience Letters</i> , 2021, 754, 135894.	1.0	9
302	Nutraceutical and therapeutic potential of Phycocyanobilin for treating Alzheimer's disease. <i>Journal of Biosciences</i> , 2021, 46, 1.	0.5	16
303	The Effect of Alkaloid Extracted from <i>Huperzia Phlegmaria</i> on Cognitive Deficits Scopolamine-Induced in Mice. <i>Current Bioactive Compounds</i> , 2021, 17, 267-278.	0.2	1
304	Understanding familial Alzheimer's disease: The fit-stay-trim mechanism of $\beta$ -secretase. <i>Wiley Interdisciplinary Reviews: Computational Molecular Science</i> , 2022, 12, e1556.	6.2	8
305	Discovery and Characterization of Selective and Ligand-Efficient DYRK Inhibitors. <i>Journal of Medicinal Chemistry</i> , 2021, 64, 11709-11728.	2.9	11
306	Cellular and pathological heterogeneity of primary tauopathies. <i>Molecular Neurodegeneration</i> , 2021, 16, 57.	4.4	85
307	Production of Therapeutic Single-Chain Variable Fragments (ScFv) in <i>Pichia pastoris</i> . <i>Methods in Molecular Biology</i> , 2022, 2313, 151-167.	0.4	2
308	The Role of Adaptive and Innate Immunity in Alzheimer's Disease. , 2021, , 213-232.		0
309	High Glycemic Diet Is Related to Brain Amyloid Accumulation Over One Year in Preclinical Alzheimer's Disease. <i>Frontiers in Nutrition</i> , 2021, 8, 741534.	1.6	8
310	Amino acid-functionalized chitosan beads for in vitro copper ions uptake in the presence of histidine. <i>International Journal of Biological Macromolecules</i> , 2021, 188, 421-431.	3.6	10
311	<i>Artemisia absinthium</i> improves spatial performance and neuronal injury induced by amyloid- $\beta$ in the CA1 hippocampal area of male Wistar rats. <i>Neurobiology of Learning and Memory</i> , 2021, 185, 107506.	1.0	0
312	Presenilin-Deficient Neurons and Astrocytes Display Normal Mitochondrial Phenotypes. <i>Frontiers in Neuroscience</i> , 2020, 14, 586108.	1.4	6
313	Neurological Disease. , 2021, , 717-749.		0
315	Overview of the Alzheimer's Disease Pathology and Potential Therapeutic Targets. , 2007, , 1-27.		7

#	ARTICLE	IF	CITATIONS
316	Cdk5 as a Drug Target for Alzheimer's Disease. , 2008, , 283-299.		2
317	Dementia: Genes, Environments, Interactions. , 2014, , 201-231.		2
318	Cell-to-Cell Transmission of $\beta$ -Synuclein Aggregates. Methods in Molecular Biology, 2012, 849, 347-359.	0.4	45
319	PET Neuroimaging in Dementia Conditions. , 2021, , 211-282.		7
320	The Aged Dog as a Natural Model of Alzheimer's Disease Progression. , 2017, , 69-92.		2
323	Deep brain two-photon NIR fluorescence imaging for study of Alzheimer's disease. , 2018, , .		1
324	BEYOND AMYLOID: The Next Generation of Alzheimer's Disease Therapeutics. Molecular Interventions: Pharmacological Perspectives From Biology, Chemistry and Genomics, 2007, 7, 261-270.	3.4	46
325	Interactions between Amyloid- $\beta$ and Hemoglobin: Implications for Amyloid Plaque Formation in Alzheimer's Disease. PLoS ONE, 2012, 7, e33120.	1.1	85
326	Gesell Developmental Schedules scores and the relevant factors in children with Down syndrome. Journal of Pediatric Endocrinology and Metabolism, 2020, 33, 539-546.	0.4	4
327	Evidence for the progression through S-phase in the ectopic cell cycle re-entry of neurons in Alzheimer disease. Aging, 2009, 1, 382-388.	1.4	73
328	ACE2 activator diminazene aceturate ameliorates Alzheimer's disease-like neuropathology and rescues cognitive impairment in SAMP8 mice. Aging, 2020, 12, 14819-14829.	1.4	27
329	Motor deficits are independent of axonopathy in an Alzheimer's disease mouse model of TgCRND8 mice. Oncotarget, 2017, 8, 97900-97912.	0.8	8
330	p-Benzoquinone as a Privileged Scaffold of Pharmacological Significance: A Review. Mini-Reviews in Medicinal Chemistry, 2020, 20, 1586-1609.	1.1	12
331	Exploring the Potential of Neuroproteomics in Alzheimer's Disease. Current Topics in Medicinal Chemistry, 2020, 20, 2263-2278.	1.0	12
332	Mechanism-based treatments for Alzheimer's disease. Dialogues in Clinical Neuroscience, 2009, 11, 159-169.	1.8	18
333	Resveratrol and Neuroprotection: Impact and Its Therapeutic Potential in Alzheimer's Disease. Frontiers in Pharmacology, 2020, 11, 619024.	1.6	89
334	Neuroprotective effect of emodin against Alzheimer's disease via Nrf2 signaling in U251 cells and APP/PS1 mice. Molecular Medicine Reports, 2020, 23, .	1.1	20
335	Down Syndrome Model of Alzheimer's Disease: Beyond Trisomy 21 Nondisjunction. , 0, , .		1

#	ARTICLE	IF	CITATIONS
336	Characterization of an APP/tau rat model of Alzheimer's disease by positron emission tomography and immunofluorescent labeling. <i>Alzheimer's Research and Therapy</i> , 2021, 13, 175.	3.0	8
337	Finite-time stability and optimal control of a stochastic reaction-diffusion model for Alzheimer's disease with impulse and time-varying delay. <i>Applied Mathematical Modelling</i> , 2022, 102, 511-539.	2.2	12
339	MOLECULAR AND CELLULAR MECHANISMS OF ALZHEIMER'S DISEASE DEVELOPMENT. <i>Fiziolohichniy Zhurnal</i> (Kiev, Ukraine: 1994), 2010, 56, 127-142.	0.1	0
340	Lesion-Induced Vertebrate Models of Alzheimer Dementia. <i>Neuromethods</i> , 2011, , 295-345.	0.2	3
341	Towards Effective Treatment Strategies for Alzheimers disease (AD). <i>Journal of Developing Drugs</i> , 2012, 01, .	0.9	0
342	Dementia: Alzheimer's disease. , 2012, , 333-343.		1
343	Neurodegenerative Disorders: Dementia and Parkinsonism, Lumping Together or Splitting Apart?. , 2014, , 1-16.		0
344	Mitochondrial Defects and Oxidative Stress in Alzheimer Disease. <i>The Neuroscience Journal of Shefaye Khatam</i> , 2014, 2, 85-94.	0.4	2
345	Modern approach in the therapy of Alzheimer's disease. <i>Uchenye Zapiski Sankt-Peterburgskogo Gosudarstvennogo Medicinskogo Universiteta Im Akad I P Pavlova</i> , 2014, 21, 6-10.	0.0	0
346	Alzheimer-Associated Pathology in the Extracellular Space. <i>Advances in Anatomy, Embryology and Cell Biology</i> , 2015, , 75-93.	1.0	1
347	Amyloid imaging of dementia using the radioligand <sup>18</sup> F-AV-45 (Florbetapir F 18). <i>No Junkan Taisha = Cerebral Blood Flow and Metabolism</i> , 2015, 26, 11-18.	0.1	0
348	Organic Disorders of the Brain. , 2016, , 299-324.		0
349	Neurodegenerative Disorders. , 2017, , 1-23.		0
351	Neurodegenerative Disorders. , 2018, , 589-612.		0
354	Amyloid Beta. <i>Advances in Medical Diagnosis, Treatment, and Care</i> , 2019, , 235-251.	0.1	2
355	Recent Advances in the Quest for Treatment and Management of Alzheimer and Other Dementia. <i>Open Journal of Medicinal Chemistry</i> , 2019, 09, 1-35.	0.7	1
360	Alzheimer's disease and Down syndrome. , 2020, , 283-297.		0
361	Alzheimer's Disease: The Role of Mutations in Protein Folding. <i>Advances in Experimental Medicine and Biology</i> , 2020, 1195, 227-236.	0.8	2

#	ARTICLE	IF	CITATIONS
362	Human adipose-derived stem cells reduce receptor-interacting protein 1, receptor-interacting protein 3, and mixed lineage kinase domain-like pseudokinase as necroptotic markers in rat model of Alzheimer's disease. <i>Indian Journal of Pharmacology</i> , 2020, 52, 392.	0.4	9
363	Optical Imaging Probes for Amyloid Diseases in Brain. <i>Neuromethods</i> , 2020, , 157-182.	0.2	2
365	Alzheimer's disease biomarkers in animal models: closing the translational gap. <i>American Journal of Neurodegenerative Disease</i> , 2013, 2, 108-20.	0.1	19
370	Interaction of Amyloidogenic Proteins with Membranes and Molecular Mechanism for the Development of Alzheimer's disease. , 2019, 2, .		2
371	Osteoblastic Swedish mutant APP expedites brain deficits by inducing endoplasmic reticulum stress-driven senescence. <i>Communications Biology</i> , 2021, 4, 1326.	2.0	4
372	Proliferation of Tau 304-380 Fragment Aggregates through Autocatalytic Secondary Nucleation. <i>ACS Chemical Neuroscience</i> , 2021, 12, 4406-4415.	1.7	19
373	Classifying Early and Late Mild Cognitive Impairment Stages of Alzheimer's Disease by Analyzing Different Brain Areas. , 2020, , .		2
374	Neurodegenerative disease by SRS microscopy. , 2022, , 501-514.		0
375	Neurogenetic disorders across the lifespan: from aberrant development to degeneration. <i>Nature Reviews Neurology</i> , 2022, 18, 117-124.	4.9	19
376	A Review of the Current Mammalian Models of Alzheimer's Disease and Challenges That Need to Be Overcome. <i>International Journal of Molecular Sciences</i> , 2021, 22, 13168.	1.8	31
377	Diagnostic Accuracy of Blood-Based Biomarker Panels: A Systematic Review. <i>Frontiers in Aging Neuroscience</i> , 2022, 14, 683689.	1.7	13
378	Verteporfin is a substrate-selective $\beta$ -secretase inhibitor that binds the amyloid precursor protein transmembrane domain. <i>Journal of Biological Chemistry</i> , 2022, 298, 101792.	1.6	3
379	Role of Mitochondrial Protein Import in Age-Related Neurodegenerative and Cardiovascular Diseases. <i>Cells</i> , 2021, 10, 3528.	1.8	8
386	Amyloid B-Protein Aggregation at Physiologically Relevant Concentrations. A Critical Role of Membranes.. , 2020, 3, .		0
387	Superoxide Reduction by Cu-Amyloid Beta Peptide Complexes: A Density Functional Theory Study. <i>European Journal of Inorganic Chemistry</i> , 2022, 2022, .	1.0	4
388	A History of Senile Plaques: From Alzheimer to Amyloid Imaging. <i>Journal of Neuropathology and Experimental Neurology</i> , 2022, 81, 387-413.	0.9	6
390	Ion Channels and Neurodegenerative Disease Aging Related. <i>Biochemistry</i> , 0, , .	0.8	2
391	Identify Biomarkers of Alzheimer's Disease Based on Multi-task Canonical Correlation Analysis and Regression Model. <i>Journal of Molecular Neuroscience</i> , 2022, 72, 1749-1763.	1.1	2

#	ARTICLE	IF	CITATIONS
392	Ultrasound-Mediated Bioeffects in Senescent Mice and Alzheimer's Mouse Models. <i>Brain Sciences</i> , 2022, 12, 775.	1.1	3
393	Modulation of High-Fat Diet-Induced Brain Oxidative Stress by Ferulate-Rich Germinated Brown Rice Ethyl Acetate Extract. <i>Molecules</i> , 2022, 27, 4907.	1.7	6
394	CD33 isoforms in microglia and Alzheimer's disease: Friend and foe. <i>Molecular Aspects of Medicine</i> , 2023, 90, 101111.	2.7	18
395	Amyloid B-Protein Aggregation at Physiologically Relevant Concentrations. A Critical Role of Membranes. , 2020, 3, .		0
396	Hippocampal morphological atrophy and distinct patterns of structural covariance network in Alzheimer's disease and mild cognitive impairment. <i>Frontiers in Psychology</i> , 0, 13, .	1.1	4
397	Nicandra physalodes Extract Exerts Antiaging Effects in Multiple Models and Extends the Lifespan of <i>Caenorhabditis elegans</i> via DAF-16 and HSF-1. <i>Oxidative Medicine and Cellular Longevity</i> , 2022, 2022, 1-13.	1.9	1
398	Structural Determinant of $\beta^2$ -Amyloid Formation: From Transmembrane Protein Dimerization to $\beta^2$ -Amyloid Aggregates. <i>Biomedicines</i> , 2022, 10, 2753.	1.4	8
399	Interaction of Amyloidogenic Proteins with Membranes and Molecular Mechanism for the Development of Alzheimer's disease. , 2019, 2, .		3
400	Design, Synthesis, and Biological Evaluation of Novel Chromanone Derivatives as Multifunctional Agents for the Treatment of Alzheimer's Disease. <i>ACS Chemical Neuroscience</i> , 2022, 13, 3488-3501.	1.7	5
401	Lyn Kinase Structure, Regulation, and Involvement in Neurodegenerative Diseases: A Mini Review. , 2023, 1, 23-38.		2
402	An ongoing journey of chalcone analogues as single and multi-target ligands in the field of Alzheimer's disease: A review with structural aspects. <i>Life Sciences</i> , 2023, 320, 121568.	2.0	7
404	Finding the falsification threshold of the toxic proteinopathy hypothesis in neurodegeneration. <i>Handbook of Clinical Neurology</i> / Edited By P J Vinken and G W Bruyn, 2023, , 143-154.	1.0	6
405	Protein Self-Assembly at the Liquid-Surface Interface. Surface-Mediated Aggregation Catalysis. <i>Journal of Physical Chemistry B</i> , 2023, 127, 1880-1889.	1.2	0
406	Learning from the amyloid hypothesis: adaptability, brevity, and clarity of ideas. <i>Neurological Sciences</i> , 2023, 44, 2177-2178.	0.9	3
413	Concerns about the Amyloid Cascade Hypothesis and Reappraisals. , 2023, , 167-183.		1
414	Step by Step Toward an Amyloid Beta Peptide-Based Hypothesis of Alzheimer's Disease. , 2023, , 135-166.		0
415	Ignorance or Conspiracy? Or Just an Amyloid Firewall that Blocks Alternative Ideas?. , 2023, , 185-226.		0
420	The supersaturation perspective on the amyloid hypothesis. <i>Chemical Science</i> , 2023, 15, 46-54.	3.7	2

#	ARTICLE	IF	CITATIONS
421	Fat and Alzheimerâ€™s Disease. , 2023, , 67-89.		0